Top

Published in:

01-09-2019 | Lung Cancer | Original Paper

ADA activity is decreased in lymphocytes from patients with advanced stage of lung cancer

Authors: Daniela Zanini, Leandro Henrique Manfredi, Luana Paula Pelinson, Victor Camera Pimentel, Andréia Machado Cardoso, Viviane do Carmo Araújo Gonçalves, Cláudia Bertoncelli dos Santos, Jessié Martins Gutierres, Vera Maria Morsch, Daniela Bitencourt Rosa Leal, Maria Rosa Chitolina Schetinger

Published in: Medical Oncology | Issue 9/2019

Abstract

Cigarette smoking is directly associated with lung cancer. Non-small cell lung carcinoma (NSCLC) represents approximately 80% from all types of lung cancer. This latter is hard to diagnose and to treat due to the lack of symptoms in early stages of the disease. The aim of this study was to evaluate ADA activity and the expression of P2X7, A1, and A2A receptors and in lymphocytes. In addition, the profile of pro-inflammatory and anti-inflammatory cytokines serum levels of patients with lung cancer in advanced stage was evaluated. Patients (n = 13) previously treated for lung cancer at stage IV (UICC) with chemotherapy had their blood collected. Cancer patients showed a decrease in ADA activity and an increase in A1 receptor expression in lymphocytes when compared to the control group. Moreover, patients exhibited an increase in IL-6 and TNF-α, while IL-17 and INF-ϒ serum levels were lower in patients with lung cancer. The decreased ADA activity and the increase in A1 receptor expression may contribute to adenosine pro-tumor effects by increasing IL-6 and TNF-α and decreasing IL-17 and INF-γ serum levels. Our data show an indirect evidence that purinergic signaling may have a role in promoting a profile of cytokines levels that favors tumor progression.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA. 2016;66(1):7–30. https://doi.org/10.3322/caac.21332.CrossRefPubMed

CP SBW. World Cancer Report. IARC Press. 2014:350-2.

Dziedzic DA, Rudzinski P, Langfort R, Orlowski T. Risk factors for local and distant recurrence after surgical treatment in patients with non-small-cell lung cancer. Clin Lung Cancer. 2016;2:25. https://doi.org/10.1016/j.cllc.2015.12.013.CrossRef

Roca M, Roca IC, Mihaescu T. Lung cancer—a comorbidity in chronic obstructive pulmonary disease. Rev Med Chir Soc Med Nat Iasi. 2012;116(4):1055–62.PubMed

Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45. https://doi.org/10.1016/S0140-6736(00)04046-0.CrossRefPubMed

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. https://doi.org/10.1038/nature01322.CrossRefPubMedPubMedCentral

Onuchic AC, Chammas R. Câncer e o microambiente tumoral. Rev Med (São Paulo). 2010;89(1):21–31.CrossRef

Fukuyama T, Ichiki Y, Yamada S, Shigematsu Y, Baba T, Nagata Y, et al. Cytokine production of lung cancer cell lines: correlation between their production and the inflammatory/immunological responses both in vivo and in vitro. Cancer Sci. 2007;98(7):1048–54. https://doi.org/10.1111/j.1349-7006.2007.00507.x.CrossRefPubMed

Yamaguchi T, Yamamoto Y, Yokota S, Nakagawa M, Ito M, Ogura T. Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn J Clin Oncol. 1998;28(12):740–4.CrossRefPubMed

10.

De Vita F, Orditura M, Auriemma A, Infusino S, Catalano G. Serum concentrations of proinflammatory cytokines in advanced non small cell lung cancer patients. J Exp Clin Cancer Res. 1998;17(4):413–7.PubMed

11.

Kanthi YM, Sutton NR, Pinsky DJ. CD39: interface between vascular thrombosis and inflammation. Curr Atheroscler Rep. 2014;16(7):425. https://doi.org/10.1007/s11883-014-0425-1.CrossRefPubMedPubMedCentral

12.

Rapaport E. Treatment of human tumor cells with ADP or ATP yields arrest of growth in the S phase of the cell cycle. J Cell Physiol. 1983;114(3):279–83. https://doi.org/10.1002/jcp.1041140305.CrossRefPubMed

13.

Spychala J. Tumor-promoting functions of adenosine. Pharmacol Therap. 2000;87(2–3):161–73.CrossRef

14.

Burnstock G. Purinergic signalling—an overview. Novartis Foundation symposium. 2006;276:26–48; discussion -57, 275–81.

15.

Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev. 2007;87(2):659–797. https://doi.org/10.1152/physrev.00043.2006.CrossRefPubMed

16.

Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov. 2008;7(7):575–90. https://doi.org/10.1038/nrd2605.CrossRefPubMed

17.

Roger S, Jelassi B, Couillin I, Pelegrin P, Besson P, Jiang LH. Understanding the roles of the P2X7 receptor in solid tumour progression and therapeutic perspectives. Biochem Biophys Acta. 2015;1848(10 Pt B):2584–602. https://doi.org/10.1016/j.bbamem.2014.10.029.CrossRefPubMed

18.

Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn-Schmiedeberg’s Arch Pharmacol. 2000;362(4–5):299–309.CrossRef

19.

Gessi S, Merighi S, Sacchetto V, Simioni C, Borea PA. Adenosine receptors and cancer. Biochem Biophys Acta. 2011;1808(5):1400–12. https://doi.org/10.1016/j.bbamem.2010.09.020.CrossRefPubMed

20.

Decking UK, Schlieper G, Kroll K, Schrader J. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ Res. 1997;81(2):154–64.CrossRefPubMed

21.

Di Virgilio F, Vuerich M. Purinergic signaling in the immune system. Auton Neurosci. 2015;191:117–23. https://doi.org/10.1016/j.autneu.2015.04.011.CrossRefPubMed

22.

Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Investig Suppl. 1968;97:77–89.

23.

Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.CrossRefPubMed

24.

Morgan E, Varro R, Sepulveda H, Ember JA, Apgar J, Wilson J, et al. Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol. 2004;110(3):252–66. https://doi.org/10.1016/j.clim.2003.11.017.CrossRefPubMed

25.

Yu Y, Liu H, Zheng S, Ding Z, Chen Z, Jin W, et al. Gender susceptibility for cigarette smoking-attributable lung cancer: a systematic review and meta-analysis. Lung Cancer. 2014;85(3):351–60. https://doi.org/10.1016/j.lungcan.2014.07.004.CrossRefPubMed

26.

INCA. Instituto Nacional do Câncer José Alencar Gomes da Silva. 2016.

27.

Zanini D, Pelinson LP, Schmatz R, Belmonte Pereira L, Curry Martins C, Baldissareli J, et al. δ-Aminolevulinate dehydratase activity in lung cancer patients and its relationship with oxidative stress. Biomed Pharmacother. 2014;68(5):603–9. https://doi.org/10.1016/j.biopha.2014.04.005.CrossRefPubMed

28.

Zanini D, Schmatz R, Pelinson LP, Pimentel VC, da Costa P, Cardoso AM, et al. Ectoenzymes and cholinesterase activity and biomarkers of oxidative stress in patients with lung cancer. Mol Cell Biochem. 2013;374(1–2):137–48. https://doi.org/10.1007/s11010-012-1513-6.CrossRefPubMed

29.

Zanini D, Schmatz R, Pimentel VC, Gutierres JM, Maldonado PA, Thome GR, et al. Lung cancer alters the hydrolysis of nucleotides and nucleosides in platelets. Biomed Pharmacother. 2012;66(1):40–5. https://doi.org/10.1016/j.biopha.2011.09.003.CrossRefPubMed

30.

Duarte RL, Paschoal ME. Molecular markers in lung cancer: prognostic role and relationship to smoking. Jornal brasileiro de pneumologia: publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia. 2006;32(1):56–65.CrossRef

31.

Granger JM, Kontoyiannis DP. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer. 2009;115(17):3919–23. https://doi.org/10.1002/cncr.24480.CrossRefPubMed

32.

Shoenfeld Y, Tal A, Berliner S, Pinkhas J. Leukocytosis in non hematological malignancies—a possible tumor-associated marker. J Cancer Res Clin Oncol. 1986;111(1):54–8.CrossRefPubMed

33.

Zhang T, Jiang Y, Qu X, Shen H, Liu Q, Du J. Evaluation of preoperative hematologic markers as prognostic factors and establishment of novel risk stratification in resected pN0 non-small-cell lung cancer. PLoS ONE. 2014;9(10):e111494. https://doi.org/10.1371/journal.pone.0111494.CrossRefPubMedPubMedCentral

34.

Langer CJ, Choy H, Glaspy JA, Colowick A. Standards of care for anemia management in oncology: focus on lung carcinoma. Cancer. 2002;95(3):613–23. https://doi.org/10.1002/cncr.10712.CrossRefPubMed

35.

Khoo HE, Ho CL, Chhatwal VJ, Chan ST, Ngoi SS, Moochhala SM. Differential expression of adenosine A1 receptors in colorectal cancer and related mucosa. Cancer Lett. 1996;106(1):17–21.CrossRefPubMed

36.

Gessi S, Varani K, Merighi S, Morelli A, Ferrari D, Leung E, et al. Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells. Br J Pharmacol. 2001;134(1):116–26. https://doi.org/10.1038/sj.bjp.0704254.CrossRefPubMedPubMedCentral

37.

Merighi S, Varani K, Gessi S, Cattabriga E, Iannotta V, Ulouglu C, et al. Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Br J Pharmacol. 2001;134(6):1215–26. https://doi.org/10.1038/sj.bjp.0704352.CrossRefPubMedPubMedCentral

38.

Schiedel AC, Lacher SK, Linnemann C, Knolle PA, Müller CE. Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: evidence for receptor-independent mechanisms. Purinergic Signal. 2013;9(3):351–65. https://doi.org/10.1007/s11302-013-9354-7.CrossRefPubMedPubMedCentral

39.

Apasov SG, Sitkovsky MV. The extracellular versus intracellular mechanisms of inhibition of TCR-triggered activation in thymocytes by adenosine under conditions of inhibited adenosine deaminase. Int Immunol. 1999;11(2):179–89.CrossRefPubMed

40.

Desrosiers MD, Cembrola KM, Fakir MJ, Stephens LA, Jama FM, Shameli A, et al. Adenosine deamination sustains dendritic cell activation in inflammation. J Immunol (Baltimore). 2007;179(3):1884–92.

41.

Gelfand EW, Lee JJ, Dosch HM. Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function. Proc Natl Acad Sci USA. 1979;76(4):1998–2002.CrossRefPubMedPubMedCentral

42.

Allard B, Turcotte M, Spring K, Pommey S, Royal I, Stagg J. Anti-CD73 therapy impairs tumor angiogenesis. Int J Cancer. 2014;134(6):1466–73. https://doi.org/10.1002/ijc.28456.CrossRefPubMed

43.

Zimmermann H, Zebisch M, Strater N. Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal. 2012;8(3):437–502. https://doi.org/10.1007/s11302-012-9309-4.CrossRefPubMedPubMedCentral

44.

Auchampach JA. Adenosine receptors and angiogenesis. Circ Res. 2007;101(11):1075–7. https://doi.org/10.1161/CIRCRESAHA.107.165761.CrossRefPubMedPubMedCentral

45.

Koszalka P, Golunska M, Urban A, Stasilojc G, Stanislawowski M, Majewski M, et al. Specific activation of A3, A2A and A1 adenosine receptors in CD73-knockout mice affects B16F10 melanoma growth, neovascularization, angiogenesis and macrophage infiltration. PLoS ONE. 2016;11(3):e0151420. https://doi.org/10.1371/journal.pone.0151420.CrossRefPubMedPubMedCentral

46.

Zhou Y, Schneider DJ, Blackburn MR. Adenosine signaling and the regulation of chronic lung disease. Pharmacol Therap. 2009;123(1):105–16. https://doi.org/10.1016/j.pharmthera.2009.04.003.CrossRef

47.

Chen R, Alvero AB, Silasi DA, Steffensen KD, Mor G. Cancers take their Toll–the function and regulation of Toll-like receptors in cancer cells. Oncogene. 2008;27(2):225–33. https://doi.org/10.1038/sj.onc.1210907.CrossRefPubMed

48.

Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 2014;26(1):54–74. https://doi.org/10.1016/j.smim.2014.01.001.CrossRefPubMed

49.

Di Virgilio F. Purines, purinergic receptors, and cancer. Cancer Res. 2012;72(21):5441–7. https://doi.org/10.1158/0008-5472.CAN-12-1600.CrossRefPubMed

50.

Erdmann AA, Gao ZG, Jung U, Foley J, Borenstein T, Jacobson KA, et al. Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood. 2005;105(12):4707–14. https://doi.org/10.1182/blood-2004-04-1407.CrossRefPubMedPubMedCentral

51.

Huang RY, Chen GG. Cigarette smoking, cyclooxygenase-2 pathway and cancer. Biochem Biophys Acta. 2011;1815(2):158–69. https://doi.org/10.1016/j.bbcan.2010.11.005.CrossRefPubMed

52.

Enewold L, Mechanic LE, Bowman ED, Zheng YL, Yu Z, Trivers G, et al. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomark Prev. 2009;18(1):215–22. https://doi.org/10.1158/1055-9965.epi-08-0705.CrossRef

Title: ADA activity is decreased in lymphocytes from patients with advanced stage of lung cancer
Authors: Daniela Zanini
Leandro Henrique Manfredi
Luana Paula Pelinson
Victor Camera Pimentel
Andréia Machado Cardoso
Viviane do Carmo Araújo Gonçalves
Cláudia Bertoncelli dos Santos
Jessié Martins Gutierres
Vera Maria Morsch
Daniela Bitencourt Rosa Leal
Maria Rosa Chitolina Schetinger
Publication date: 01-09-2019
Publisher: Springer US
Keywords: Lung Cancer
Lung Cancer
Cytokines
Lung Cancer
Published in: Medical Oncology / Issue 9/2019
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-019-1301-1

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2019

EMT-related protein expression in polyploid giant cancer cells and their daughter cells with different passages after triptolide treatment

Examination of clonal evolution in chronic lymphocytic leukemia

Identification of important invasion and proliferation related genes in adrenocortical carcinoma

A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells